Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (ARMP) is a clinical-stage biotechnology company pioneering bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. This page serves as the definitive source for verified news and press releases related to ARMP's scientific advancements, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on clinical trial progress, manufacturing developments from their cGMP facility, and collaborations with government health agencies. The curated news collection covers essential updates including therapeutic candidate evaluations, intellectual property developments, and peer-reviewed research publications.
With antibiotic resistance identified as a critical global health challenge by the WHO, Armata's focus on targeted phage therapies positions its updates as particularly relevant for healthcare investors and infectious disease specialists. Regular monitoring of this resource provides insight into the company's progress toward addressing Pseudomonas aeruginosa, Staphylococcus aureus, and other priority pathogens.
Bookmark this page for streamlined access to Armata's latest scientific communications, presented with contextual clarity for both professional investors and biotechnology stakeholders.
Armata Pharmaceuticals (NYSE American: ARMP) announced a poster presentation at the 2024 Military Health System Research Symposium. The presentation highlights two phage development programs: inhaled AP-PA02 for Pseudomonas aeruginosa bronchiectasis and intravenous AP-SA02 for Staphylococcus aureus bacteremia. The company is 80% through enrollment in its Phase 1b/2a study (diSArm) of AP-SA02, expecting completion by end of 2024. AP-SA02 development is supported by a $21.6 million Department of Defense grant. Both phage candidates have been well-tolerated in clinical trials, allowing for higher doses. Armata plans to advance both candidates to pivotal Phase 3 trials in 2025. Preliminary data suggests intravenous AP-SA02 is active in all subjects, with longer persistence in some, potentially indicating in vivo amplification. Inhaled AP-PA02 shows promise as an alternative to inhaled antibiotics for P. aeruginosa bronchiectasis.
Armata Pharmaceuticals (NYSE American: ARMP) has appointed David House as Senior Vice President, Finance, effective August 16th. House brings extensive experience in senior accounting and finance roles within life sciences companies. CEO Dr. Deborah Birx highlighted House's expertise as valuable for advancing Armata's programs, AP-PA02 and AP-SA02, and preparing for pivotal studies next year.
House's previous roles include Corporate Controller at ZO Skin Health, where he managed global accounting operations and financial reporting. He also held key positions at Peregrine Pharmaceuticals and Avid Bioservices, implementing ASC 606 and managing SEC reporting. House's career spans various accounting and financial management positions in healthcare and technology sectors. He holds a Bachelor's degree in Business Administration with an Accounting concentration and has previously held a California CPA license.
Armata Pharmaceuticals (NYSE American: ARMP) announced its Q2 2024 results and provided a corporate update. Key developments include:
1. Completed enrollment in Phase 2 Tailwind study of AP-PA02 for Non-Cystic Fibrosis Bronchiectasis, with topline data expected in H2 2024.
2. Received $5.25 million in non-dilutive funding from the U.S. Department of Defense for the Phase 2a diSArm study of AP-SA02 for S. aureus bacteremia.
3. Completed build-out of advanced biologics manufacturing facility with five cGMP clean rooms.
Financial highlights: No grant revenue in Q2 2024 vs $1.0 million in Q2 2023. R&D expenses increased to $8.5 million. Loss from operations was $11.9 million. Cash and equivalents stood at $26.4 million as of June 30, 2024.
Armata Pharmaceuticals (NYSE American: ARMP) has received an additional $5.25 million in non-dilutive funding from the U.S. Department of Defense to support its ongoing diSArm clinical trial of AP-SA02. This Phase 1b/2a trial is evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia, a serious bloodstream infection often resistant to antibiotics. The study is currently 68% enrolled, aiming for approximately 50 subjects. It's designed as a randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy.
Armata Pharmaceuticals (ARMP) has completed enrollment for its Phase 2 Tailwind study of inhaled AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection. The study, which follows the successful SWARM-P.a. trial in cystic fibrosis patients, evaluates the safety, tolerability, and efficacy of AP-PA02. Topline results are expected in the second half of 2024, with plans to commence a pivotal Phase 3 trial in 2025. The study includes two cohorts: one receiving phage-only therapy and another receiving a combination with inhaled antibiotics. The final follow-up visit is scheduled for August 7, 2024.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company, will present at the Viruses of Microbes 2024 conference in Cairns, Australia. The event occurs from July 15-19, 2024. Steven Branston, the Australia Site Head, will deliver a presentation titled 'Advancing Bacteriophage Therapy from Discovery to Clinical Trials' on July 18 at the Phage Therapy Session 2 – Clinical Application. The presentation will cover the progress in bacteriophage therapy, a promising approach for treating antibiotic-resistant bacterial infections.
Armata Pharmaceuticals, Inc. released its First Quarter 2024 financial results and corporate update. The company secured a $35 million credit agreement, continued clinical trials for phage therapeutics, and advanced its biologics manufacturing facility. Dr. Deborah Birx, CEO, highlighted progress in developing treatments for bacterial infections, with positive enrollment in clinical studies. The financials showed a grant revenue of $1.0 million, reduced research and development expenses, increased general and administrative expenses, resulting in a loss of $10.2 million from operations. Armata held $37.9 million in cash as of March 31, 2024.
FAQ
What is the current stock price of Armata Pharmctcl (ARMP)?
What is the market cap of Armata Pharmctcl (ARMP)?
